Cytokine Signaling in Tumor Progression

Cytokines are molecules that play critical roles in the regulation of a wide range of normal functions leading to cellular proliferation, differentiation and survival, as well as in specialized cellular functions enabling host resistance to pathogens. Cytokines released in response to infection, inflammation or immunity can also inhibit cancer development and progression. The predominant intracellular signaling pathway triggered by cytokines is the JAK-signal transducer and activator of transcription (STAT) pathway. Knockout mice and clinical human studies have provided evidence that JAK-STAT proteins regulate the immune system, and maintain immune tolerance and tumor surveillance. Moreover, aberrant activation of the JAK-STAT pathways plays an undeniable pathogenic role in several types of human cancers. Thus, in combination, these observations indicate that the JAK-STAT proteins are promising targets for cancer therapy in humans. The data supporting this view are reviewed herein.

[1]  Yibing Shan,et al.  Crystal structures of the Jak2 pseudokinase domain and the pathogenic mutant V617F , 2012, Nature Structural &Molecular Biology.

[2]  Y. Chung,et al.  Somatic Mutations of JAK1 and JAK3 in Acute Leukemias and Solid Cancers , 2008, Clinical Cancer Research.

[3]  W. Leonard,et al.  Jaks and STATs: biological implications. , 1998, Annual review of immunology.

[4]  Hua Yu,et al.  The STATs of cancer — new molecular targets come of age , 2004, Nature Reviews Cancer.

[5]  B. Dörken,et al.  Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. , 2004, Blood.

[6]  H. Huynh,et al.  Sunitinib (SUTENT, SU11248) suppresses tumor growth and induces apoptosis in xenograft models of human hepatocellular carcinoma. , 2009, Current cancer drug targets.

[7]  G. Freeman,et al.  Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. , 2016, Cancer research.

[8]  E. Tartour,et al.  A Decrease of Regulatory T Cells Correlates With Overall Survival After Sunitinib-based Antiangiogenic Therapy in Metastatic Renal Cancer Patients , 2010, Journal of immunotherapy.

[9]  A. Schäffer,et al.  The hyper IgE syndrome and mutations in TYK2. , 2007, Immunity.

[10]  R. Dhir,et al.  Stat3 activation in prostatic carcinomas , 2002, The Prostate.

[11]  M. Loh,et al.  Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. , 2000, Molecular cell.

[12]  D. Rickman,et al.  Pre-TCR expression cooperates with TEL-JAK2 to transform immature thymocytes and induce T-cell leukemia. , 2007, Blood.

[13]  B. Rini,et al.  MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy. , 2011, International immunopharmacology.

[14]  J. Ghysdael,et al.  A transgenic mouse model for TEL-JAK2-induced B-cell lymphoma/leukemia , 2006, Leukemia.

[15]  S. Korsmeyer,et al.  Jak3 Selectively Regulates Bax and Bcl-2 Expression To Promote T-Cell Development , 2001, Molecular and Cellular Biology.

[16]  J. Spivak,et al.  Disease burden at the progenitor level is a feature of primary myelofibrosis: a multivariable analysis of 164 JAK2 V617F-positive myeloproliferative neoplasm patients. , 2011, Experimental hematology.

[17]  Josef M. Penninger,et al.  CD45 is a JAK phosphatase and negatively regulates cytokine receptor signalling , 2001, Nature.

[18]  Richard Clark,et al.  A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. , 2004, Blood.

[19]  R. Levine,et al.  The JAK 2 V 617 F activating tyrosine kinase mutation is an infrequent event in both “ atypical ” myeloproliferative disorders and myelodysplastic syndromes , 2005 .

[20]  C. Pecquet,et al.  Mining for JAK-STAT mutations in cancer. , 2008, Trends in biochemical sciences.

[21]  W. Vainchenker,et al.  JAK/STAT signaling in hematological malignancies , 2013, Oncogene.

[22]  Paul Shinn,et al.  Selective targeting of JAK/STAT signaling is potentiated by Bcl-xL blockade in IL-2-dependent adult T-cell leukemia , 2015, Retrovirology.

[23]  S. Ambudkar,et al.  WHI-P154 enhances the chemotherapeutic effect of anticancer agents in ABCG2-overexpressing cells , 2014, Cancer science.

[24]  Pawel Dobrzanski,et al.  Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders. , 2008, Blood.

[25]  R. Berger,et al.  The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells , 2001, Oncogene.

[26]  Hui Song,et al.  Upregulation of MEK5 by Stat3 promotes breast cancer cell invasion and metastasis. , 2017, Oncology reports.

[27]  Stephen L. Abrams,et al.  Contributions of the Raf/MEK/ERK, PI3K/PTEN/Akt/mTOR and Jak/STAT pathways to leukemia , 2008, Leukemia.

[28]  P. Scherle,et al.  The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers , 2012, Journal of clinical pharmacology.

[29]  Jamie B. Spangler,et al.  Insights into cytokine-receptor interactions from cytokine engineering. , 2015, Annual review of immunology.

[30]  Hua Yu,et al.  Sunitinib Induces Apoptosis and Growth Arrest of Medulloblastoma Tumor Cells by Inhibiting STAT3 and AKT Signaling Pathways , 2010, Molecular Cancer Research.

[31]  David P Steensma,et al.  The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both "atypical" myeloproliferative disorders and myelodysplastic syndromes. , 2005, Blood.

[32]  E. Engle,et al.  Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib , 2012, Blood Cancer Journal.

[33]  G. Noronha,et al.  Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors. , 2008, Cancer cell.

[34]  Mario Cazzola,et al.  A gain-of-function mutation of JAK2 in myeloproliferative disorders. , 2005, The New England journal of medicine.

[35]  W. Weimar,et al.  The Jak Inhibitor CP‐690,550 Preserves the Function of CD4+CD25brightFoxP3+ Regulatory T Cells and Inhibits Effector T Cells , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[36]  H. Hirai,et al.  Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo , 2017, Leukemia.

[37]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[38]  H. Kantarjian,et al.  Phase I evaluation of XL019, an oral, potent, and selective JAK2 inhibitor. , 2014, Leukemia research.

[39]  L. Lang.  FDA approves sorafenib for patients with inoperable liver cancer. , 2008, Gastroenterology.

[40]  H. Hamada,et al.  Inhibition of the antigen‐induced activation of rodent mast cells by putative Janus kinase 3 inhibitors WHI‐P131 and WHI‐P154 in a Janus kinase 3‐independent manner , 2005, British journal of pharmacology.

[41]  V. Najfeld,et al.  Phase I dose escalation study of lestaurtinib in patients with myelofibrosis , 2015, Leukemia & lymphoma.

[42]  W. Vainchenker,et al.  New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients. , 2006, Seminars in thrombosis and hemostasis.

[43]  Mark E Flanagan,et al.  Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. , 2014, Journal of medicinal chemistry.

[44]  Hongbing Shen,et al.  Effects of potentially functional polymorphisms in suppressor of cytokine signaling 3 (SOCS3) on the risk of head and neck squamous cancer , 2017, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[45]  T. Waldmann,et al.  CP-690,550, a therapeutic agent, inhibits cytokine-mediated Jak3 activation and proliferation of T cells from patients with ATL and HAM/TSP. , 2011, Blood.

[46]  François Girodon,et al.  The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera. , 2006, Blood.

[47]  Steven M Holland,et al.  JAKs and STATs in immunity, immunodeficiency, and cancer. , 2013, The New England journal of medicine.

[48]  N. Magné,et al.  NGF-induced TrkA/CD44 association is involved in tumor aggressiveness and resistance to lestaurtinib , 2015, Oncotarget.

[49]  S. Serrano,et al.  Lestaurtinib Inhibition of the JAK/STAT Signaling Pathway in Hodgkin Lymphoma Inhibits Proliferation and Induces Apoptosis , 2011, PloS one.

[50]  Hui Sun,et al.  Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP) , 2017, PloS one.

[51]  Simon C Watkins,et al.  Constitutive activation of Stat3 signaling abrogates apoptosis in squamous cell carcinogenesis in vivo. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[52]  D. Levy,et al.  Identification of a Stat3-dependent transcription regulatory network involved in metastatic progression. , 2009, Cancer research.

[53]  M. Carroll,et al.  TEL/platelet-derived growth factor receptor beta activates phosphatidylinositol 3 (PI3) kinase and requires PI3 kinase to regulate the cell cycle. , 2002, Blood.

[54]  S. Grant,et al.  Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process. , 2012, Blood.

[55]  S. Rane,et al.  Janus kinases: components of multiple signaling pathways , 2000, Oncogene.

[56]  Ayalew Tefferi,et al.  Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. , 2010, The New England journal of medicine.

[57]  Kenneth Offit,et al.  A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms , 2009, Nature Genetics.

[58]  C. Eaves,et al.  BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. , 2008, Cancer research.

[59]  Catriona Jamieson,et al.  Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  S. Groshen,et al.  Phase I trial of lestaurtinib for children with refractory neuroblastoma: a new approaches to neuroblastoma therapy consortium study , 2011, Cancer Chemotherapy and Pharmacology.

[61]  X. P. Liu,et al.  4-(3'-Bromo-4'hydroxylphenyl)-amino-6,7-dimethoxyquinazoline: a novel quinazoline derivative with potent cytotoxic activity against human glioblastoma cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[62]  Z. Parveen,et al.  Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490 , 2015, Journal of biomolecular structure & dynamics.

[63]  J. O’Shea,et al.  Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. , 2010, Immunity.

[64]  J. Wood,et al.  Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia , 2011, Blood cancer journal.

[65]  R. Kralovics,et al.  Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. , 2006, Blood.

[66]  M. Fraga,et al.  Contribution of JAK2 mutations to T-cell lymphoblastic lymphoma development , 2015, Leukemia.

[67]  J. Dick,et al.  Expression of TEL-JAK2 in primary human hematopoietic cells drives erythropoietin-independent erythropoiesis and induces myelofibrosis in vivo , 2006, Proceedings of the National Academy of Sciences.

[68]  Z. Nagy,et al.  Selective inhibitor of Janus tyrosine kinase 3, PNU156804, prolongs allograft survival and acts synergistically with cyclosporine but additively with rapamycin. , 2002, Blood.

[69]  S Goelz,et al.  Differential regulation of the alpha/beta interferon-stimulated Jak/Stat pathway by the SH2 domain-containing tyrosine phosphatase SHPTP1 , 1995, Molecular and cellular biology.

[70]  Massimo Gadina,et al.  The JAK-STAT pathway: impact on human disease and therapeutic intervention. , 2015, Annual review of medicine.

[71]  J. Hong,et al.  Cell-based Immunotherapy for Colorectal Cancer with Cytokine-induced Killer Cells , 2016, Immune network.

[72]  Nuala Moran.  Incyte comes of age with JAK inhibitor approval , 2012, Nature Biotechnology.

[73]  J. Casanova,et al.  Inborn errors of human JAKs and STATs. , 2012, Immunity.

[74]  Clifford Liongue,et al.  Alternative TEL-JAK2 fusions associated with T-cell acute lymphoblastic leukemia and atypical chronic myelogenous leukemia dissected in zebrafish , 2012, Haematologica.

[75]  P. Rothman,et al.  Abl Oncogene Bypasses Normal Regulation of JAK/STAT Activation , 2004, Cell cycle.

[76]  S. Constantinescu,et al.  The JAK-STAT pathway and hematopoietic stem cells from the JAK2 V617F perspective , 2012, JAK-STAT.

[77]  S. Bhattacharya,et al.  Signaling through the JAK/STAT pathway, recent advances and future challenges. , 2002, Gene.

[78]  J. Bauman,et al.  Discovery of a JAK3-Selective Inhibitor: Functional Differentiation of JAK3-Selective Inhibition over pan-JAK or JAK1-Selective Inhibition. , 2016, ACS chemical biology.

[79]  M. Munchhof,et al.  The specificity of JAK3 kinase inhibitors. , 2008, Blood.

[80]  A. Tefferi.  JAK and MPL mutations in myeloid malignancies , 2008, Leukemia & lymphoma.

[81]  R. Jove,et al.  Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. , 2009, Cancer research.

[82]  N. Yoo,et al.  Absence of JAK2 Exon 12 Mutation in Acute Leukemias , 2008, Acta Haematologica.

[83]  M. Cazzola,et al.  Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders. , 2008, Blood.

[84]  M. Masuda,et al.  Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. , 2002, Cancer research.

[85]  L. Coussens,et al.  CD4(+) T cells regulate pulmonary metastasis of mammary carcinomas by enhancing protumor properties of macrophages. , 2009, Cancer cell.